Next-Generation MICA-Targeting Cancer Therapies

The invention envisions a paradigm shift in cancer treatment by integrating bi-specific T-cell engagers, gene editing tools, and nanobody-based imaging agents to selectively target and modify MICA-expressing cancer cells, enhancing specificity and efficacy.

The original patent disclosed anti-MICA antigen binding fragments, fusion molecules, and cells that express them, but had limitations in terms of specificity and efficacy. The new inventive concept addresses these limitations by proposing a system that combines multiple technologies to create a more targeted and effective cancer treatment.

The new inventive concept comprises a bi-specific T-cell engager that selectively targets MICA-expressing cancer cells, a gene editing tool for in-situ modification of the T-cell engager to enhance its specificity and efficacy, and a nanobody-based imaging agent for real-time monitoring of treatment efficacy. The system enables personalized neoantigen-based cancer vaccines, fusion proteins of MICA-binding antibodies and gene editing enzymes, and devices for in-vivo detection and targeting of MICA-expressing cancer cells. The computer-implemented method for predicting the efficacy of the bi-specific T-cell engager-based cancer therapy integrates patient-specific genomic and proteomic data with in-vitro and in-vivo testing results.

The new claims introduce a novel combination of bi-specific T-cell engagers, gene editing tools, and nanobody-based imaging agents, which is not obvious from the original patent. The inventive step lies in the integration of these technologies to create a more targeted and effective cancer treatment.

Alternative embodiments may include using different gene editing tools, such as CRISPR-Cas9 or base editing, or incorporating additional imaging modalities, such as MRI or PET. Variations may include targeting different cancer biomarkers or using different types of bi-specific T-cell engagers.

The inventive concept has the potential to revolutionize cancer treatment by providing a more targeted and effective therapy. The market for cancer treatment is significant, with an estimated global value of over $150 billion by 2025. The inventive concept may be applicable to various types of cancer, including solid tumors and hematological malignancies.